Daces Teterovskas arsta prakse endokrinologija SIA

Ogre 9 trials 2 recruiting

9 Registered trials

2 Currently recruiting

Organisation

Daces Teterovskas arsta prakse endokrinologija SIA

Location

Ogre, Latvia

Identifier

ORG-100049138

Address

Brivibas Street 22, 5001, Latvia

Departments

#7305
Dace Teterovska Doctor Practice in Endocrinology
Endocrinology
N/A
NA

Clinical trials at this site (9)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting

2025-524001-33-00 Graves’ Disease 4 2026-05-22
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Graves' Disease Recruiting

2025-521920-31-00 Graves’ Disease 4 2025-11-21
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS) Ended

2023-506827-26-00 While it is well-established that long-term good glycae 5 2019-05-02
A study to evaluate the efficacy and safety of gliclazide MR in patients with type 2 diabetes inadequately controlled with dapagliflozin wit… Ended

2024-511408-18-00 Type 2 Diabetes inadequately controlled with dapagliflo 5 2024-07-15
Extension Study to Assess Batoclimab in Participants with TED. Ended

2024-512650-21-00 Thyroid Eye Disease (TED) 5 2023-12-13
Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease Ended

2024-512649-18-00 Thyroid Eye Disease 5 2023-06-05
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24